NCT04682457

Brief Summary

The study aims is to find out if people with type 1 diabetes diagnosed in later life (after age 30) have the same rapid loss of insulin secretion (measured using C-peptide) that occurs in younger adults with type 1 diabetes. The investigators will recruit 135 participants aged over 30 years with a clinical diagnosis of type 1 diabetes and diabetes duration ≤100 days. The investigators will also recruit a comparison group of 61 participants aged 18-30 with a clinical diagnosis of type 1 diabetes and diabetes duration ≤100 days. C-peptide will be measured during mixed meal tolerance tests (MMTT) performed at baseline, 6 months and a year. This study also aims to test a new more practical way of monitoring insulin secretion at home using a finger prick 'blood spot' rather than time consuming tests in a hospital. Finger-prick C-peptide samples will be collected after the MMTT and by the participants at home throughout the year.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
130

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2019

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

December 15, 2020

Completed
8 days until next milestone

First Posted

Study publicly available on registry

December 23, 2020

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2023

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

June 4, 2024

Status Verified

June 1, 2024

Enrollment Period

3.8 years

First QC Date

December 15, 2020

Last Update Submit

June 3, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • C-peptide value at a year

    12 month (Mixed Meal Tolerance Test) MMTT area under the curve (AUC) C-peptide.

    12 months

  • Change in C-peptide over a year

    Rate of change of MMTT AUC C-peptide over 12 months assessed at regular study visits

    12 months

Secondary Outcomes (3)

  • C-peptide value at 12 months

    12 months

  • Glucose variability & hypoglycemia

    12 months

  • Change in dried blood spot C-peptide

    12 months

Study Arms (2)

Late Onset

Participants diagnosed with Type 1 diabetes at over 30 years of age.

18 to 30

Participants diagnosed with Type 1 diabetes between 18 and 30 years of age

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Recent clinical diagnosis of type 1 diabetes

You may qualify if:

  • Adults with a clinical diagnosis of Type 1 diabetes within the previous 100 days.
  • Aged \>30 at the time of Type 1 diabetes diagnosis OR (additional early onset Type 1 diabetes cohort) aged ≥18 and ≤30 at the time of Type 1 diabetes diagnosis.
  • Insulin treated at the time of recruitment
  • Able and willing to provide informed consent.

You may not qualify if:

  • Pregnancy
  • Known monogenic diabetes
  • Known secondary diabetes (diabetes considered likely due to medication, cystic fibrosis, pancreatitis, pancreatic cancer, pancreatic surgery, hemochromatosis or Cushing's syndrome).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Royal Devon & Exeter NHS Foundation Trust

Exeter, Devon, EX2 5DW, United Kingdom

Location

Related Publications (1)

  • Thomas NJ, Lynam AL, Hill AV, Weedon MN, Shields BM, Oram RA, McDonald TJ, Hattersley AT, Jones AG. Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes. Diabetologia. 2019 Jul;62(7):1167-1172. doi: 10.1007/s00125-019-4863-8. Epub 2019 Apr 10.

    PMID: 30969375BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Serum, Plasma, DNA,

MeSH Terms

Conditions

Diabetes Mellitus, Type 1Disease Progression

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Angus Jones, MBBS MRCP

    NIHR Exeter Clinical Research Facility

    STUDY DIRECTOR
  • Nicholas Thomas, MRCP

    NIHR Exeter Clinical Research Facility

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 15, 2020

First Posted

December 23, 2020

Study Start

November 1, 2019

Primary Completion

September 1, 2023

Study Completion

December 31, 2023

Last Updated

June 4, 2024

Record last verified: 2024-06

Locations